Gilead, Galapagos clear another PhII hurdle for filgotinib, but can they hope to catch up with Novartis’ Cosentyx?
Gilead and Galapagos have cleared another hurdle in a broad-ranging program to advance filgotinib into the market as a blockbuster candidate. But this latest achievement still leaves them way behind a surging Novartis in a packed field of rivals.
Researchers say that the drug hit clearly positive endpoints for moderate to severe active ankylosing spondylitis. That includes the primary endpoint, which took a look at a disease activity score at week 12. There they saw a drop from baseline of 1.5 compared to 0.6 for the control arm. There was also a 76% ASAS20 response for the drug arm compared to 40% in the placebo group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
